Statistical strategies to improve the efficiency of molecular studies of colorectal cancer prognosis

British Journal of Cancer

Volumn 99, Issue 12, 2008, Pages 2001-2005

  Qu, P ^a   Chu, H ^b   Ibrahim, J G ^b   Peacock, J ^c   Shen, X J ^c   Tepper, J ^c   Sandler, R S ^c   Keku, T O ^c  

^a Fred Hutchinson Cancer Research Center   (United States)

^b IL   (United States)

^c UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

Efficiency; Molecular markers; Stopping rule; Survival; Variability

Indexed keywords

B RAF KINASE; CYCLIN D1; K RAS PROTEIN; KI 67 ANTIGEN; MOLECULAR MARKER; PROTEIN MDM2; PROTEIN MLH1; PROTEIN P53; UVOMORULIN;

ARTICLE; CLINICAL EVALUATION; COLORECTAL CANCER; CONTROLLED STUDY; GENE MUTATION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MICROSATELLITE INSTABILITY; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROGNOSIS;

BIOLOGICAL MARKERS; COLORECTAL NEOPLASMS; HUMANS; MUTATION; PROGNOSIS; PROTEINS;

EID: 57449113575     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/sj.bjc.6604792     Document Type: Article

References (12)

1. Andreyev HJ, Norman AR, Cunningham D, Oates JR, Clarke PA (1998) Kirsten ras mutations in patients with colorectal cancer: the multicenter 'RASCAL' study. J Natl Cancer Inst 90: 675-684
2. Angelopoulou K, Diamandis EP (1998) Identification of deletions and insertions in the p53 gene using multiplex PCR and high-resolution fragment analysis: application to breast and ovarian tumors. J Clin Lab Anal 12: 250-256
3. Boland CR, Sato J, Saito K, Carethers JM, Marra G, Laghi L, Chauhan DP (1998) Genetic instability and chromosomal aberrations in colorectal cancer: a review of the current models. Cancer Detect Prev 22: 377-382
4. Curtin K, Slattery ML, Holubkov R, Edwards S, Holden JA, Samowitz WS (2004) p53 alterations in colon tumors: a comparison of SSCP/sequencing and immunohistochemistry. Appl Immunohistochem Mol Morphol 12: 380 -386
5. Friedman LM, Furberg CD, DeMets DL (1999) Fundamentals of clinical trials. pp 94-129. Springer-Verlag: New York
6. Gryfe R, Kim H, Hsieh ET, Aronson MD, Holowaty EJ, Bull SB, Redston M, Gallinger S (2000) Tumor microsatellite instability and clinical outcome in young patients with colorectal cancer. N Engl J Med 342: 69-77
7. Hardingham JE, Butler WJ, Roder D, Dobrovic A, Dymock RB, Sage RE, Roberts-Thomson IC (1998) Somatic mutations, acetylator status, and prognosis in colorectal cancer. Gut 42: 669-672
8. Hoos A, Cordon-Cardo C (2001) Tissue microarray profiling of cancer specimens and cell lines: opportunities and limitations. Lab Invest 81: 1331-1338
9. Hsieh FY, Lavori PW (2000) Sample-size calculations for the Cox proportional hazards regression model with nonbinary covariates. Control Clin Trials 21: 552-560
10. Kononen J, Bubendorf L, Kallioniemi A, Barlund M, Schraml P, Leighton S, Torhorst J, Mihatsch MJ, Sauter G, Kallioniemi OP (1998) Tissue microarrays for high-throughput molecular profiling of tumor specimens. Nat Med 4: 844-847
11. Samowitz WS, Curtin K, Schaffer D, Robertson M, Leppert M, Slattery ML (2000) Relationship of Ki-ras mutations in colon cancers to tumor location, stage, and survival: a population-based study. Cancer Epidemiol Biomarkers Prev 9: 1193-1197
12. Schoenfeld DA (1983) Sample-size formula for the proportional-hazards regression model. Biometrics 39: 499-503